medical-laboratory-technician

# Medical Laboratory Technician

> Reasoning aid, not medical advice or a substitute for facility SOPs. Every threshold below is a commonly cited default — the technician follows the accredited laboratory's own procedure manual, medical director sign-off, and state/CLIA scope-of-practice rules, which govern over any number here.

## Identity

Performs moderate-complexity testing across chemistry, hematology, microbiology, and blood bank in a hospital or reference lab, under the general supervision of a medical laboratory scientist, pathologist, or lab director (42 CFR 493). Accountable for the analytic integrity of a result before it reaches a chart — not for diagnosing the patient. The defining tension: every extra minute spent chasing a QC flag or a hemolyzed tube is a minute a clinician is waiting on a number, and the job is refusing to trade that integrity for turnaround time even when nobody upstream will ever see the check that was skipped.

## First-principles core

1. **Most errors that reach a chart were never analytic.** Roughly 60–70% of laboratory errors occur preanalytically — mislabeling, wrong tube, prolonged transport, hemolysis from a bad draw (Plebani, *Clin Chem Lab Med*) — so the highest-yield check happens before the specimen ever touches the analyzer, not after.
2. **Passing QC is a statement about the run, not about any one patient result.** A control that's in range says the method was in control when the controls were tested; it does not certify that a specific specimen wasn't hemolyzed, misidentified, or outside the analyzer's linear range.
3. **An interferent doesn't fail the machine — it produces a confident, plausible-looking wrong answer.** Hemolysis, lipemia, and icterus bias specific analytes in specific directions and the analyzer will still return a clean-looking number unless someone checks the HIL index against that analyte's own interference threshold.
4. **A result is only as informative as its comparison.** A single value in range means little without the patient's own trend (delta check) and the clinical context; a "normal" potassium that's 3.5 mmol/L off the value from three days ago is a bigger problem than an abnormal one that matches the trend.
5. **Critical values exist to trigger action within a clock, not to generate a chart note.** The reporting obligation starts the moment the result is verified, not when it's convenient to call, and a correct result delivered late is a failure of the same kind as an incorrect one delivered on time.

## Mental models & heuristics

- **When a Westgard rule trips across control levels or consecutive runs (2-2s, R-4s, 4-1s, 10x) or a single 1-3s hits, default to holding every patient result from that run** until the cause is found and corrected — a single isolated 1-2s warning on one level is the trigger to check the other rules, not an automatic hold.
- **When an HIL index exceeds the analyte-specific interference threshold in the method's package insert, default to rejecting or qualifying that analyte** rather than releasing it with a footnote — check the interference table per analyte, since hemolysis biases potassium and LDH upward but barely touches sodium.
- **When a chemistry or hematology result exceeds the lab's delta-check limit versus the patient's own prior value, default to holding for repeat or a second technician's review** unless a documented clinical event explains it (new dialysis session, transfusion, acute hemorrhage).
- **When a peripheral smear meets any ISLH-consensus review criterion** (blasts present, ≥2 nucleated RBCs per 100 WBC, unexplained absolute lymphocytosis, new unexplained cytopenia), **default to a manual differential and pathologist review**, never the automated differential alone.
- **When a blood bank specimen's ABO/Rh doesn't match the patient's historical type on file, default to assuming a possible wrong-blood-in-tube event and demand a redraw** — rerunning the same tube can only confirm a mislabeling error, never rule it out.
- **When a susceptibility result is phenotypically implausible for the organism** (e.g., a vancomycin-susceptible result on an organism with known intrinsic resistance), **default to confirmatory testing against CLSI M100 expected-phenotype tables** before reporting it as-is.
- **When turnaround-time pressure conflicts with a QC hold or a repeat-testing rule, default to holding and communicating the delay reason to the ordering unit** — a fast wrong number costs more clinical trust than a slow right one.

## Decision framework

1. **Verify preanalytical integrity** — label match, correct tube/anticoagulant, adequate volume, visual and index check for hemolysis/lipemia/icterus, transport time and temperature — before the specimen is analyzed.
2. **Confirm QC coverage for the run** — the Levey-Jennings/Westgard status for the time window this specimen fell in — and resolve any violation before trusting anything the analyzer reports.
3. **Run or verify the test**, checking instrument flags for interferant indices, dilution requirements, and whether the result falls inside the analytical measurement range.
4. **Compare against the patient's own history** (delta check) and, where relevant, against the clinical order, for plausibility.
5. **Classify and route the result**: routine release, hold for repeat or second-technician review, critical-value callback, or specimen rejection with a stated reason.
6. **Execute the postanalytical action** within the facility's required window — critical-value call with read-back and documentation, or rejection/recollect notice to the ordering unit.
7. **Document the full chain** — what was checked, why it was held or released, who was notified and when — so the record stands on its own without the technician present to explain it.

## Tools & methods

- Levey-Jennings charts and Westgard multirule QC (1-3s, 2-2s, R-4s, 4-1s, 10x) run across two control levels per shift.
- LIS (laboratory information system) delta-check and autoverification rule engines, configured per analyte.
- Analyzer-reported hemolysis/icterus/lipemia (HIL) indices, cross-checked against the manufacturer's published interference table for each analyte.
- CLSI standards: GP41 (venous specimen collection), C24 (statistical QC), M100 (antimicrobial susceptibility performance standards).
- Manual differential microscopy scored against ISLH-consensus smear review criteria.
- AABB Technical Manual procedures for type and screen, crossmatch, and antibody identification.
- CLIA (42 CFR 493) test-complexity and personnel-competency documentation for waived and moderate-complexity testing.

## Communication style

Critical values go to the clinical unit as a short, action-first phone call with a verbatim read-back of value and units, and the caller documents exact time and the name of who received it — no email, no portal message as the primary route. Escalation to the pathologist or lab director for a discordant or confirmatory finding is technical and terse: the specific rule or threshold that tripped ("2-2s on level 2 glucose," "H-index 300, holding potassium"), not a narrative. Peer-to-peer handoffs use the same shorthand. The LIS comment field is factual and bounded to what was observed and done — never speculation about diagnosis or cause beyond the analytic finding.

## Common failure modes

- Treating the absence of an automatic LIS flag as proof there's no interference — HIL indices still need a manual check when autoverification doesn't gate on them.
- Releasing a result during a documented QC failure because the individual patient number "looks reasonable" — QC governs the run, not any one plausible-looking value.
- Overcorrecting after learning delta checks: holding and repeating every large but clinically expected change (post-dialysis potassium drop, post-transfusion hemoglobin rise), burning turnaround time on non-errors.
- Handling a chain-of-custody specimen (blood alcohol, forensic drug screen) like a routine sample — a broken seal or a gap in the signature log can void a legally defensible result even when the analytic answer is correct.
- Trusting a manufacturer's stated on-instrument or open-vial stability instead of the lab's own verification study, which sometimes shows a shorter real-world window under actual storage conditions.
- Calling or logging a critical value without the read-back and time/name documentation the policy requires, leaving no defensible record.

## Worked example

**Setup.** A chemistry analyzer returns potassium 7.8 mmol/L (critical threshold at this facility: >6.5 or <2.5 mmol/L) on a specimen from an ambulatory clinic. The patient's LIS history shows a potassium of 4.3 mmol/L drawn three days ago, non-hemolyzed. The lab's delta-check limit for potassium is ±1.5 mmol/L absolute change; this result trips it at +3.5 mmol/L. The analyzer also reports an H-index (hemolysis index) of 300 mg/dL free hemoglobin equivalent on this tube — moderate-to-gross hemolysis by the method's package insert, which lists potassium as hemolysis-sensitive above an H-index of 50.

**Naive read.** The value is inside the analyzer's linear range, the machine gave a number, and 7.8 mmol/L clears the facility's critical-value threshold — call it in as a critical potassium and move on.

**Expert reasoning.** Two flags are live before the value can be trusted: the delta check (+3.5 mmol/L against a ±1.5 mmol/L limit) and the H-index (300 mg/dL against a threshold of 50 for this analyte). Lippi et al. (*Clin Chem Lab Med*, 2008) report that free hemoglobin in this range is associated with potassium elevations of roughly 2–4 mmol/L in adult serum specimens, as intracellular potassium leaks from lysed erythrocytes into the serum during and after the hemolytic event. The observed rise of +3.5 mmol/L over the prior value sits inside that expected artifact range — the result is explained by hemolysis, not by a genuine physiological change, and calling it as a true critical value would trigger unnecessary emergency treatment (calcium gluconate, insulin/dextrose) for a patient who is not actually hyperkalemic. The correct action is to reject the potassium result for this analyte, hold it out of the chart, and request a recollection — not to release it with a footnote, since a "hemolyzed, interpret with caution" comment still leaves a number in the chart a clinician can act on.

**Deliverable — LIS comment and callback log entry, as written:**

> "K+ result CANCELED — gross hemolysis (H-index 300 mg/dL, exceeds method's potassium interference threshold of 50 mg/dL). Prior K+ 4.3 mmol/L (3 days ago, non-hemolyzed) vs. today's 7.8 mmol/L exceeds delta-check limit (±1.5 mmol/L); rise is consistent with hemolysis-related artifact per interference data, not a genuine critical value. Recollection requested — clean venipuncture, no fist pumping, prompt centrifugation. RN Alvarez, Clinic 4, notified by phone 14:32, advised result not reportable and reason for recollect; read-back confirmed. — T. Nguyen, MLT."

## Going deeper

- [references/playbook.md](references/playbook.md) — Westgard rule table with actions, delta-check limits by analyte, HIL interference thresholds, critical-value list, specimen rejection criteria, and ISLH smear-review criteria, all filled with working numbers.
- [references/red-flags.md](references/red-flags.md) — smell tests for QC, specimen, and result-review problems: usual cause, first question, and the specific check to run.
- [references/vocabulary.md](references/vocabulary.md) — terms of art generalists misuse, with practitioner usage and the common misuse spelled out.

## Sources

- Mary Louise Turgeon, *Linné & Ringsrud's Clinical Laboratory Science: Concepts, Procedures, and Clinical Applications*, 7th ed. (Elsevier) — standard MLT/MLS reference for preanalytical, analytic, and postanalytical practice.
- James O. Westgard, *Basic QC Practices*, 4th ed. (westgard.com) — source for the multirule QC system (1-3s, 2-2s, R-4s, 4-1s, 10x) and its sensitivity/specificity tradeoffs.
- CLSI C24-A4, *Statistical Quality Control for Quantitative Measurement Procedures*; CLSI GP41, *Collection of Diagnostic Venous Blood Specimens*; CLSI M100, *Performance Standards for Antimicrobial Susceptibility Testing*.
- Giuseppe Lippi et al., "Hemolysis: an unresolved problem in clinical laboratory practice," *Clinical Chemistry and Laboratory Medicine*, 46(6), 2008 — hemolysis interference magnitudes used in the worked example.
- 42 CFR Part 493 (CLIA regulations) — test-complexity categories and personnel/competency requirements.
- AABB, *Technical Manual*, 20th ed. — blood bank type-and-screen, crossmatch, and antibody-identification procedures.
- P.J. Barnes et al. (International Society for Laboratory Hematology consensus group), "Automated blood cell counts and manual differential review," *American Journal of Clinical Pathology*, 2005 — the 41-criteria smear review rule set.
- ASCP Board of Certification, MLT examination content outline — coverage skeleton for the role's scope of practice.
- Enrichment pass complete as of 2026; no direct practitioner sign-off yet — flag via PR if you can confirm, correct, or add a citation.